MEY™ | Next-Generation Superfood, Nutraceutical & Pharmaceutical Ingredients

MEY™: One Ingredient Platform. Multiple Industries. Extraordinary Potential.

Solmeyea Biotech is introducing MEY™, its proprietary, non-GMO, white microalgae-based ingredient platform forfood, functional nutrition, nutraceutical and pharmaceutical applications. Developed through years of biotechnology research and industrial demonstration, MEY™ combines proteins, essential amino acids, beneficial lipids and other naturally occurring nutrients in a versatile biomass. Produced through Solmeyea's patented CO₂-utilisation and fermentation technology, MEY™ combines nutritional functionality with resource-efficient manufacturing.

We seek global partners for product innovation, scientific validation, ingredient supply and long-term collaboration.

1. Food & Beverage: Functional Nutrition at Scale

MEY™ helps manufacturers enhance nutritional profiles and develop innovative functional products.

Applications include:

• Ready-to-drink beverages, protein shakes and smoothies

• Dairy and alternatives, including yogurts and cream cheeses

• Bakery, snacks, cereals and protein-enriched foods

• Plant-based meat and seafood alternatives

• Sports nutrition, healthy ageing and specialised nutrition

Solmeyea has developed and pilot-validated MEY™ beverages and is preparing its first consumer launch. We welcome joint development, ingredient qualification, paid formulation trials, distribution and long-term supply agreements.

2. Nutraceuticals: Unlocking Microalgae's Health Potential

Solmeyea is developing a scientific pathway to investigate MEY™'s potential physiological benefits. Research priorities include digestion, nutrient bioaccessibility, gut microbiome interactions, metabolic and cardiovascular health, immune-related pathways and healthy ageing. Planned activities include in-vitro digestibility simulations, bioactivity assessments and subsequent human clinical studies with European research partners. We seek nutraceutical manufacturers, clinical research organisations and specialised nutrition companies to validate MEY™ and develop evidence-based products. Health claims require scientific substantiation and regulatory compliance.

3. Pharma: Advanced Research & Bioactive Discovery

Solmeyea is exploring its microalgae platform for pharmaceutical research, medical nutrition and bioactive ingredient development.

Collaborative R&D opportunities include:

• Identification and characterisation of bioactive fractions

• Investigation of microalgae-derived peptides and amino acids

• In-vitro biological screening and functional assays

• Ingredient fractionation, purification and processing

• Exploratory medical nutrition and pharmaceutical applications

We welcome pharmaceutical R&D teams, CDMOs, biotechnology companies and research institutions to design validation programmes and explore future applications. Pharmaceutical applications remain exploratory, subject to research, qualification and regulation.

Technology, Infrastructure & Competitive Advantages

Solmeyea operates a 1,200 m² biotechnology demonstration and R&D facility in Athens, Greece. Our patented platform combines industrial CO₂ gas fermentation with non-GMO microalgae cultivation, convertingcaptured emissions into nutritional ingredients.

Key achievements:

• Patented biotechnology and additional EU/US IP filings

• Several million in cumulative European grants

• Recognition through the EIC, CBE JU, EIT Food and ESA

• Pilot-validated functional beverages developed with Tetra Pak

• International research and industrial collaborations

• Progress towards first-of-a-kind industrial scale-up

• Selection of MEY™ space-nutrition applications for an upcoming ISS mission

Solmeyea is advancing industrial scale-up alongside international B2B and consumer commercialisation.

Partnership Opportunities at SWITCH 2026

We want to connect with:

• Food & beverage manufacturers: Formulation, development and ingredient offtake

• Nutraceutical companies: Functional nutrition and scientific validation

• Pharmaceutical companies: Collaborative R&D and bioactive screening

• Ingredient distributors: Regional distribution and market access

• Research institutions: Digestibility, bioactivity and clinical studies

• Industrial partners: Technology deployment, investment and scale-up

Geographical focus: Singapore, Southeast Asia, Europe, North America and global markets.

Our ambition is a global ingredient platform supporting better nutrition, resilient food systems and sustainable biotechnology.

Join us in bringing MEY™ to global markets.

www.solmeyea.com